Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase 3 2Phase 1/2 2

Status

Completed 6Unknown 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 2Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Solid Tumors 1Solid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Hypoxia 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Completed × TH 302 × Clear all
NCT01497444 2020-02-06

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Alliance for Clinical Trials in Oncology

Phase 1 Completed
24 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms

NCT01833546 2018-10-15

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
20 enrolled 35 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01485042 2017-09-01

PATH

Duke University

Phase 1 Completed
50 enrolled
Other solid neoplasm

Solid Tumors

NCT02076230 2016-06-10

A Phase 1 TH-302 Mass Balance Trial

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
10 enrolled
Other solid neoplasm

Solid Tumor

NCT01149915 2015-05-07

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Threshold Pharmaceuticals

Phase 1 Completed
40 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00495144 2012-07-27

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1 Completed
129 enrolled

Hypoxia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡